Osteoporosis is a condition in which bones become weak and prone to fractures. Fractures typically occur in the wrist, spine or hip, and can often lead to permanently impaired mobility. Women over 50 are at high risk of developing osteoporosis; which may due to the loss of estrogen that occurs after menopause. While studies have linked estrogen levels to bone health, the exact details of this connection are not entirely clear.
Researchers at Tokyo Medical and Dental University (TMDU); have described a new molecular link between estrogen and bone aging, which may eventually lead to new strategies to treat postmenopausal osteoporosis. Bone is a complex tissue, consisting of a matrix of proteins and minerals that give it the flexibility and strength to support body movement. Bone also contains several types of specialized cells; including osteocytes, that help to maintain this matrix.
Healthy bone structure
Over a person’s lifetime, many factors can affect how healthy bone structure is maintaining. One of these factors is the female sex hormone, estrogen. “Over the last few decades, they have learned that estrogen plays an important role in maintaining a functional bone matrix,” corresponding authors Tomoki Nakashima and Hiroshi Takayanagi explain. “Exactly how estrogen does this, though, is not fully understood.
The laboratory recently discovered that the bone matrix is maintained by a protein called Sema3A; which is secreting by osteocytes. This led us to suspect that there might a mechanistic relationship between estrogen and Sema3A.” Sema3A does, indeed, appear to link to estrogen. The researchers found that blood serum levels of the protein decrease in premenopausal women as they get older, and drop even further once women reach menopause.
But how, at the biological level, are estrogen and Sema3A related? And what is Sema3A doing in bone tissue? To answer these questions; the researchers turned to mice. Scientists know that after removing the ovaries of mice, subsequent estrogen loss causes their bone mass to decrease. This can prevent, however, by giving the mice an extra supply of the hormone. The team took advantage of this to explore the function of Sema3A.
The osteoblast lineage cells
“When they genetically removed Sema3A from the osteoblast lineage cells (including osteocytes); they found that intravenous estrogen no longer prevented bones from deteriorating after an ovariectomy,” lead author Mikihito Hayashi says. “In addition, we found that Sema3A sets off a chain of signaling events that promote the survival of osteocytes.
This suggests that Sema3A serves as a key mechanistic link between estrogen and bone maintenance. They believe that as women lose estrogen with age and Sema3A levels drop off; osteocytes begin to die and bone loses the ability to maintain its supportive structure.” The researchers hope that the discovery of Sema3A as a major player in bone health and the signaling molecules it controls in bone may offer new therapeutic approaches to treating osteoporosis.